{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:57:35Z","timestamp":1789721855190,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T00:00:00Z","timestamp":1429142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/npp.2015.108","type":"journal-article","created":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T09:21:08Z","timestamp":1429176068000},"page":"2489-2498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers"],"prefix":"10.1038","volume":"40","author":[{"given":"Margaret","family":"Haney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-0073","authenticated-orcid":false,"given":"Divya","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillinder","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-2332","authenticated-orcid":false,"given":"Ziva D","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,16]]},"reference":[{"key":"BFnpp2015108_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMct0801733","volume":"359","author":"RF Anton","year":"2008","unstructured":"Anton RF (2008). Naltrexone for the management of alcohol dependence. N Engl J Med 359: 715\u2013721.","journal-title":"N Engl J Med"},{"key":"BFnpp2015108_CR2","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003\u20132017.","journal-title":"JAMA"},{"key":"BFnpp2015108_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40429-014-0011-1","volume":"1","author":"R Balter","year":"2014","unstructured":"Balter R, Cooper ZD, Haney M (2014). Novel pharmacologic approaches to treating cannabis use disorder (invited review). Curr Addict Rep 1: 137\u2013143.","journal-title":"Curr Addict Rep"},{"key":"BFnpp2015108_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00213-010-1995-4","volume":"212","author":"G Bedi","year":"2010","unstructured":"Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD et al (2010). Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 212: 675\u2013686.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0306-4522(01)00210-X","volume":"104","author":"D Braida","year":"2001","unstructured":"Braida D, Pozzi M, Cavallini R, Sala M (2001). Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 104: 923\u2013926.","journal-title":"Neuroscience"},{"key":"BFnpp2015108_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.drugalcdep.2013.04.013","volume":"132","author":"JD Buckner","year":"2013","unstructured":"Buckner JD, Zvolensky MJ, Ecker AH (2013). Cannabis use during a voluntary quit attempt: an analysis from ecological momentary assessment. Drug Alcohol Depend 132: 610\u2013616.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1037\/0022-006X.74.2.307","volume":"74","author":"AJ Budney","year":"2006","unstructured":"Budney AJ, Moore BA, Rocha HL, Higgins ST (2006). Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 74: 307\u2013316.","journal-title":"J Consult Clin Psychol"},{"key":"BFnpp2015108_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2006.04.014","volume":"86","author":"AJ Budney","year":"2007","unstructured":"Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B (2007). Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86: 22\u201329.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2011.06.011","volume":"120","author":"M Cerd\u00e1","year":"2012","unstructured":"Cerd\u00e1 M, Wall M, Keyes KM, Galea S, Hasin D (2012). Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend 120: 22\u201327.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0306-4603(89)90017-8","volume":"14","author":"LD Chait","year":"1989","unstructured":"Chait LD, Pierri J (1989). Some physical characteristics of NIDA marijuana cigarettes. Addict Behav 14: 61\u201367.","journal-title":"Addict Behav"},{"key":"BFnpp2015108_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K et al (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63: 210\u2013218.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2015108_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.03.001","volume":"96","author":"SD Comer","year":"2008","unstructured":"Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL (2008). The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96: 1\u201315.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1369-1600.2007.00095.x","volume":"13","author":"ZD Cooper","year":"2008","unstructured":"Cooper ZD, Haney M (2008). Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 13: 188\u2013195.","journal-title":"Addict Biol"},{"key":"BFnpp2015108_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00213-010-1875-y","volume":"211","author":"ZD Cooper","year":"2010","unstructured":"Cooper ZD, Haney M (2010). Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology 211: 141\u2013148.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0022-3565(25)23815-0","volume":"271","author":"SM Evans","year":"1994","unstructured":"Evans SM, Troisi JR 2nd, Griffiths RR (1994). Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 271: 683\u2013694.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2015108_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0376-8716(87)90079-2","volume":"20","author":"RW Foltin","year":"1987","unstructured":"Foltin RW, Brady JV, Fischman MW, Emurian CS, Dominitz J (1987). Effects of smoked marijuana on social interaction in small groups. Drug Alcohol Depend 20: 87\u201393.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0376-8716(99)00128-3","volume":"59","author":"MK Greenwald","year":"2000","unstructured":"Greenwald MK, Stitzer ML (2000). Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 59: 261\u2013275.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.npp.1301243","volume":"32","author":"M Haney","year":"2007","unstructured":"Haney M (2007). Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 32: 1391\u20131403.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015108_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1369-1600.2008.00121.x","volume":"14","author":"M Haney","year":"2009","unstructured":"Haney M (2009). Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14: 9\u201321.","journal-title":"Addict Biol"},{"key":"BFnpp2015108_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.biopsych.2012.07.028","volume":"73","author":"M Haney","year":"2013","unstructured":"Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD et al (2013a). Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry 73: 242\u2013248.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2015108_CR21","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/npp.2013.54","volume":"38","author":"M Haney","year":"2013","unstructured":"Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW (2013b). Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38: 1557\u20131565.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015108_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00213-002-1279-8","volume":"166","author":"M Haney","year":"2003","unstructured":"Haney M, Bisaga A, Foltin RW (2003). Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 166: 77\u201385.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.npp.1300310","volume":"29","author":"M Haney","year":"2004","unstructured":"Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C et al (2004). Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158\u2013170.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015108_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","volume":"199","author":"M Haney","year":"2008","unstructured":"Haney M, Spealman R (2008). Controversies in translational research: drug self-administration. Psychopharmacology (Berl) 199: 403\u2013419.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2015108_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s002130050849","volume":"141","author":"M Haney","year":"1999","unstructured":"Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141: 395\u2013404.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00213-005-2234-2","volume":"181","author":"CL Hart","year":"2005","unstructured":"Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW (2005). Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 181: 237\u2013243.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","volume":"194","author":"MA Huestis","year":"2007","unstructured":"Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G et al (2007). Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 194: 505\u2013515.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","volume":"58","author":"MA Huestis","year":"2001","unstructured":"Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET et al (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58: 322\u2013328.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2015108_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1176\/appi.ajp.2008.08020304","volume":"165","author":"N Jayaram-Lindstr\u00f6m","year":"2008","unstructured":"Jayaram-Lindstr\u00f6m N, Hammarberg A, Beck O, Franck J (2008). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165: 1442\u20131448.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2015108_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00213-003-1693-6","volume":"173","author":"Z Justinova","year":"2004","unstructured":"Justinova Z, Tanda G, Munzar P, Goldberg SR (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology 173: 186\u2013194.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.addbeh.2006.08.009","volume":"32","author":"RM Kadden","year":"2007","unstructured":"Kadden RM, Litt MD, Kabela-Cormier E, Petry NM (2007). Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 32: 1220\u20131236.","journal-title":"Addict Behav"},{"key":"BFnpp2015108_CR32","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL (2011). Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377: 1506\u20131513.","journal-title":"Lancet"},{"key":"BFnpp2015108_CR33","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1517\/14656560903048959","volume":"10","author":"MW Lee","year":"2009","unstructured":"Lee MW, Fujioka K (2009). Naltrexone for the treatment of obesity: review and update. Exp Opin Pharmacother 10: 1841\u20131845.","journal-title":"Exp Opin Pharmacother"},{"key":"BFnpp2015108_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","volume":"116","author":"FR Levin","year":"2011","unstructured":"Levin FR, Mariani JJ, Brooks DJ, Cheng W, Nunes EV (2011). Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116: 142\u2013150.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR35","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1360-0443.2006.01609.x","volume":"101","author":"BE Lozano","year":"2006","unstructured":"Lozano BE, Stephens RS, Roffman RA (2006). Abstinence and moderate use goals in the treatment of marijuana dependence. Addiction 101: 1589\u20131597.","journal-title":"Addiction"},{"key":"BFnpp2015108_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1037\/0022-006X.72.3.455","volume":"72","author":"Marijuana Treatment Project Research Group","year":"2004","unstructured":"Marijuana Treatment Project Research Group (2004). Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 72: 455\u2013466.","journal-title":"J Consult Clin Psychol"},{"key":"BFnpp2015108_CR37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0893-133X(02)00368-8","volume":"27","author":"BJ Mason","year":"2002","unstructured":"Mason BJ, Goodman AM, Dixon RM, Abdel Hameed MH, Hulot T, Wesnes K et al (2002). A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27: 596\u2013606.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015108_CR38","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1523\/JNEUROSCI.21-14-05344.2001","volume":"21","author":"M Navarro","year":"2001","unstructured":"Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L et al (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344\u20135350.","journal-title":"J Neurosci"},{"key":"BFnpp2015108_CR39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"SS O\u2019Malley","year":"1992","unstructured":"O\u2019Malley SS, Jaffe AJ, Chang G, Schottenfield RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881\u2013887.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2015108_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002130100919","volume":"160","author":"SS O\u2019Malley","year":"2002","unstructured":"O\u2019Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craivng and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160: 19\u201329.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s002130000666","volume":"154","author":"C Oncken","year":"2001","unstructured":"Oncken C, Van Kirk J, Kranzler HR (2001). Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology 154: 397\u2013402.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1300\/J069v19n01_06","volume":"19","author":"HM Pettinati","year":"2000","unstructured":"Pettinati HM, Volpicelli JR, Pierce JD Jr, O'Brien CP (2000). Improving naltrexone response. J Addict Dis 19: 71\u201383.","journal-title":"J Addict Dis"},{"key":"BFnpp2015108_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjp.0706757","volume":"148","author":"C Rios","year":"2006","unstructured":"Rios C, Gomes I, Devi LA (2006). Mu opioid and CB1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387\u2013395.","journal-title":"Br J Pharmacol"},{"key":"BFnpp2015108_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1369-1600.2008.00107.x","volume":"13","author":"P Robledo","year":"2008","unstructured":"Robledo P, Berrendero F, Ozaita A, Maldonado R (2008). Advances in the field of cannabinoid\u2014opioid cross-talk. Addict Biol 13: 213\u2013224.","journal-title":"Addict Biol"},{"key":"BFnpp2015108_CR45","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neuroscience.2013.04.034","volume":"248","author":"JL Scavone","year":"2013","unstructured":"Scavone JL, Sterling RC, Van Bockstaele EJ (2013). Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 248: 637\u2013654.","journal-title":"Neuroscience"},{"key":"BFnpp2015108_CR46","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s00213-004-2118-x","volume":"179","author":"M Solinas","year":"2005","unstructured":"Solinas M, Goldberg SR (2005). Involvement of mu-, delta- and kappa-opoioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology 179: 804\u2013812.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015108_CR47","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.2174\/138161281940131209142843","volume":"19","author":"WW Stoops","year":"2013","unstructured":"Stoops WW, Rush CR (2013). Agonist replacement for stimulant dependence: a review of clinical research. Curr Pharm Des 19: 7026\u20137035.","journal-title":"Curr Pharm Des"},{"key":"BFnpp2015108_CR48","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality (2012). Drug Abuse Warning Network (DAWN), 2008: National Estimates of Drug-Related Emergency Department Visits HHS Publication No. (SMA) 11-4618. SAMHSA: Rockville, MD."},{"key":"BFnpp2015108_CR49","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) (2013). Results from the 2012 National Survey on Drug Use and Health: summary of national findings NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. SAMHSA: Rockville, MD."},{"key":"BFnpp2015108_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/157488609787354396","volume":"4","author":"D Taylor","year":"2009","unstructured":"Taylor D (2009). Withdrawal of rimonabant \u2013 walking the tightrope of 21st centry pharmaceutical regulation? (Opinion). Curr Drug Safety 4: 2\u20134.","journal-title":"Curr Drug Safety"},{"key":"BFnpp2015108_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.drugalcdep.2012.08.001","volume":"128","author":"R Vandrey","year":"2013","unstructured":"Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D (2013). The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 128: 64\u201370.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpt1976203315","volume":"20","author":"K Verebey","year":"1976","unstructured":"Verebey K, Volavka J, Mule SJ et al (1976). Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 20: 315\u2013328.","journal-title":"Clin Pharmacol Ther"},{"key":"BFnpp2015108_CR53","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","volume":"49","author":"JR Volpicelli","year":"1992","unstructured":"Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876\u2013880.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2015108_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0376-8716(99)00127-1","volume":"59","author":"SR Wachtel","year":"2000","unstructured":"Wachtel SR, de Wit H (2000). Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend 59: 251\u2013260.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015108_CR55","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/FBP.0b013e328348ed22","volume":"22","author":"AA Wakley","year":"2011","unstructured":"Wakley AA, Craft RM (2011). THC-methadone and THC-naltrexone interactions on discrimination, antinociception, and locomotion in rats. Behav Pharmacol 22: 489\u2013497.","journal-title":"Behav Pharmacol"},{"key":"BFnpp2015108_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/00952990.2013.819362","volume":"40","author":"AM Weinstein","year":"2014","unstructured":"Weinstein AM, Miller H, Bluvstein I, Rapoport E, Schreiber S, Bar-Hamburger R et al (2014). Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Am J Drug Alcohol Abuse 40: 16\u201322.","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2015108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2015108","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2015108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T12:57:05Z","timestamp":1747918625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2015108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,16]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFnpp2015108"],"URL":"https:\/\/doi.org\/10.1038\/npp.2015.108","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725437358.793542282","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,16]]},"assertion":[{"value":"17 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}